Our Dividend Informer analysts like the prospects of this biotechnology company as it digests a recent large acquisition, finding the current valuation a reasonable balance of risk and reward.
The transition from growth darling to capital return veteran is not always smooth, nor linear. A large acquisition disrupted Amgen’s transition, but shareholders may ultimately be rewarded through growth if the acquisition performs.
Drug development is often a crapshoot, but an undemanding valuation means that shareholders should get a reasonable return no matter how the dice land.
